Daily Stock Analysis, GASX, Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics, Inc. was founded in 2000 and is based in Norcross, Georgia., priceseries

Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics, Inc. was founded in 2000 and is based in Norcross, Georgia.. Daily Stock Analysis
Stock Information
Open
45.03
Close
44.59
High
45.21
Low
44.23
Previous Close
45.10
Daily Price Gain
-0.51
YTD High
56.73
YTD High Date
Jan 2, 2019
YTD Low
24.44
YTD Low Date
Apr 23, 2019
YTD Price Change
-3.12
YTD Gain
-6.53%
52 Week High
78.82
52 Week High Date
Dec 24, 2018
52 Week Low
15.85
52 Week Low Date
Jul 13, 2018
52 Week Price Change
28.22
52 Week Gain
172.36%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
May 24. 2017
30.97
Jun 12. 2017
36.73
12 Trading Days
18.60%
Link
LONG
Jun 14. 2017
38.26
Jun 23. 2017
41.89
7 Trading Days
9.48%
Link
LONG
Aug 2. 2017
36.58
Aug 23. 2017
41.96
15 Trading Days
14.72%
Link
LONG
Jan 29. 2018
20.23
Feb 15. 2018
28.47
13 Trading Days
40.74%
Link
LONG
Aug 7. 2018
17.59
Aug 21. 2018
18.92
10 Trading Days
7.58%
Link
LONG
Oct 17. 2018
18.76
Nov 1. 2018
25.36
11 Trading Days
35.17%
Link
LONG
Nov 12. 2018
26.82
Dec 3. 2018
29.92
14 Trading Days
11.54%
Link
LONG
Dec 4. 2018
31.60
Dec 26. 2018
51.67
14 Trading Days
63.53%
Link
LONG
Feb 5. 2019
32.36
Feb 13. 2019
34.26
6 Trading Days
5.86%
Link
LONG
Apr 25. 2019
27.53
May 10. 2019
31.81
11 Trading Days
15.54%
Link
LONG
May 22. 2019
35.13
Jun 18. 2019
47.14
18 Trading Days
34.17%
Link
Company Information
Stock Symbol
GASX
Exchange
NASDAQ
Company URL
http://www.galectintherapeutics.com
Company Phone
678-620-3186
CEO
Peter G. Traber
Headquarters
Georgia
Business Address
4960 PEACHTREE INDUSTRIAL BOULEVARD, SUITE 240, NORCROSS, GA 30071
Sector
Equity
Industry Category
Drugs
Industry Group
Drugs - Generic
CIK
0001133416
About

Galectin Therapeutics, Inc. operates as a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease and cancer. Its drug candidates are based on the method of targeting galectin proteins, which are key mediators of biologic and pathologic function and its focus is on diseases with serious, life-threatening consequences to patients and those where current treatment options are limited. The company was founded by James C. Czirr and Anatole A. Kltyosov on July 10, 2000 and is headquartered in Norcross, GA.

Description

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company's lead product candidate includes galectin-3 inhibitor (GR-MD-02), a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis. The company, through its collaborative joint venture, Galectin Sciences, LLC with SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics, Inc. was founded in 2000 and is based in Norcross, Georgia.